Lanean...
COST-EFFECTIVENESS OF NIRAPARIB, RUCAPARIB, AND OLAPARIB FOR TREATMENT OF PLATINUM-RESISTANT, RECURRENT OVARIAN CARCINOMA
BACKGROUND: Olaparib was approved on December 19, 2014 by the US FDA as 4th-line therapy (and beyond) for patients with germline BRCA1/2 mutations; rucaparib was approved on December 19, 2016 as 3rd-line therapy (and beyond) for germline or somatic BRCA1/2-mutated recurrent disease. On June 24, 2019...
Gorde:
| Argitaratua izan da: | Gynecol Oncol |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7410501/ https://ncbi.nlm.nih.gov/pubmed/32173049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.02.030 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|